JP2005145941A - メチル1−[N6−(3−ヨードベンジル)−アデニン−9−イル]−β−D−イボフロナミドを個体に処置する方法 - Google Patents
メチル1−[N6−(3−ヨードベンジル)−アデニン−9−イル]−β−D−イボフロナミドを個体に処置する方法 Download PDFInfo
- Publication number
- JP2005145941A JP2005145941A JP2003397549A JP2003397549A JP2005145941A JP 2005145941 A JP2005145941 A JP 2005145941A JP 2003397549 A JP2003397549 A JP 2003397549A JP 2003397549 A JP2003397549 A JP 2003397549A JP 2005145941 A JP2005145941 A JP 2005145941A
- Authority
- JP
- Japan
- Prior art keywords
- meca
- dose
- administration
- individual
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract description 3
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 claims abstract description 69
- 230000036765 blood level Effects 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 3
- 230000002411 adverse Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101150046889 ADORA3 gene Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 2
- 206010016825 Flushing Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920003108 Methocel™ A4M Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007085 granulocyte colony-stimulating factor production Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002410 myeloprotective effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】個体にIB−MECAを処置して治療効果を達成する方法が提供される。該方法は、最大血中レベルが約160nMより低くなるような量および時間で、IB−MECA投与量を個体に投与することを含む。
【選択図】 なし。
Description
以下の記載および請求の範囲において「個体」という用語は、ヒトの個体を意味する。
<方法>
[試験の設計]
単回投与試験および繰り返し投与試験の二つの臨床試験を行った。両試験は、類似するグループで二重盲検し、投与量を増大させ、対照をプラセボとして設計した。
健康な若い男性、年齢は18〜45歳。
単回投与試験において、IB−MECA粉末が30% Cremophor RH40(BASF)に含まれる溶液を使用した。繰り返し投与試験では、0.5% メチルセルロース水性懸濁液(Methocel A4M Premium,The Dow Chemical Company)を使用した。両方の試験で、試験投与は、50mlの水道水で飲料として経口摂取された。
次の手順で行った。
最大濃度(Cmax)および最大濃度に達する時間(tmax)を観察した。他の薬物動態学的パラメーター(半減期、t1/2;AUC;およびクリアランス、CL/F)はWinNonlin(R)ソフトウェア−(バージョン3.0、Pharsight,Mountain View,CA,US)を使用して、非−コンパートメント法(non-compartmental methods)によって算出した。Cmaxの累積指数およびAUCは、定常状態(7日目)の値と1日目の値の比率として算出した。
IB−MECAを与えられた全ての被験者からのデータが、安全性および耐容性の分析に包含された(有害事象および実験室的安全性の計量値(variables))。数値データおよびパラメーターは、データのタイプおよび分布に従って、平均値または中間値、および他の記述的な統計を用いてまとめられた。
[試験個体群]
単回投与の試験において、平均(範囲)の年齢、体重、および身長は、それぞれ28.3(20−40)歳、75.9(63−98)kg、および177.8(167−188)cmであった。繰り返し投与試験では、平均(範囲)の年齢、体重、および身長は、それぞれ25.2(18−45)歳、75.3(56−99)kg、および178.0(163−189)cmであった。ボランティアは、二人のアジア/インド人および一人の欧州/東洋人を除いた他は全て、欧州起源の民族であった。
単回投与試験において、5mgまでの投与量のIB−MECAは、生命徴候、物理的試験、FEV1、並びに12誘導および連続心電図によって判断されるように、耐容性が良好であった。血液および尿の安全性試験において、臨床的に重大な変化はみられなかった。4人の被験者で、5mgのIB−MECAを投与した後に安静時の心拍数がわずかに上昇した。10mgを投与した後では、4人の被験者は安静時の心拍数が実質的に上昇し、そのうち2人はかなり(115拍/分)上昇し、薬物と関連していると見なされた。これら2人の被験者は悪心を起こし、彼らのうち1人は、一回嘔吐し、顔面が紅潮した。これらの変化により、より高い投与量の試験を行うことができなくなった。血圧が有意に変化した被験者はいなかったが、血圧は立位で測定しなかった。心拍数の増加は、血漿中IB−MECA濃度と密接に関係した(図1)。
全体的に、5mgの1日1回投与および4mgの1日2回投与は安全であり耐容性が良好であると考えられた。これらの投与量は、約160nM(80ng/ml)より小さいCmaxを与えるということが提示された。
Claims (6)
- 個体にIB−MECAを処置して治療効果を達成する方法であって、該方法は、最大血中レベルが約160nMより低くなるような量および時間で、IB−MECA投与量を個体に投与することを含む方法。
- 請求項1に記載の方法であって、IB−MECAが経口で投与される方法。
- 請求項2に記載の方法であって、IB−MECAが1日1回、約5mgより少ない投与量で成人個体に投与される方法。
- 請求項1に記載の方法であって、IB−MECAが約0.1mg〜約5mgの投与量で投与される方法。
- 請求項2に記載の方法であって、IB−MECAが1日2回、それぞれ約4mgより少ない投与量で成人個体に投与される方法。
- 請求項5に記載の方法であって、IB−MECAが各投与につき約0.1mg〜約4mgの投与量で投与される方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/705,262 US20050101560A1 (en) | 2003-11-12 | 2003-11-12 | Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005145941A true JP2005145941A (ja) | 2005-06-09 |
JP2005145941A5 JP2005145941A5 (ja) | 2006-01-19 |
Family
ID=34552317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003397549A Pending JP2005145941A (ja) | 2003-11-12 | 2003-11-27 | メチル1−[N6−(3−ヨードベンジル)−アデニン−9−イル]−β−D−イボフロナミドを個体に処置する方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20050101560A1 (ja) |
JP (1) | JP2005145941A (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995002604A1 (en) * | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
US5688774A (en) * | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
-
2003
- 2003-11-12 US US10/705,262 patent/US20050101560A1/en not_active Abandoned
- 2003-11-27 JP JP2003397549A patent/JP2005145941A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20050101560A1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Klecker Jr et al. | Pharmacokinetics of 2 ‘, 3’‐Dideoxycytidine in Patients with AIDS and Related Disorders | |
Montesinos et al. | Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis | |
US10265337B2 (en) | Use of A3 adenosine receptor agonist in osteoarthritis treatment | |
Reid et al. | Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors | |
AU2016226006B2 (en) | Method of treatment with tradipitant | |
ES2287804T3 (es) | Metodo para el tratamiento de esclerosis multiples. | |
US20100086483A1 (en) | Method of multidetector computed tomagraphy | |
EP3380095B1 (en) | Compositions and methods for treating ischemic stroke | |
ES2534560T3 (es) | Acetato de eslicarbazepina y su uso | |
JP6145946B2 (ja) | 併用als療法 | |
WO2008023362A2 (en) | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer | |
BR112020009477A2 (pt) | compostos e regime de dosagem para uso na prevenção ou tratamento de doenças inflamatórias e/ou autoimunes | |
KR20090032083A (ko) | 신장 기능이 손상된 개체의 이뇨 작용 개선 방법 | |
EP2806878A1 (en) | Treatment of liver conditions | |
Montamat et al. | N‐monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. | |
WO2004045627A1 (en) | A3ar agonists for the treatment of inflammatory arthritis | |
KR20180081595A (ko) | 이소성 지방 축적의 치료에 사용하기 위한 a3 아데노신 수용체 리간드 | |
JP2005145941A (ja) | メチル1−[N6−(3−ヨードベンジル)−アデニン−9−イル]−β−D−イボフロナミドを個体に処置する方法 | |
EA006776B1 (ru) | Фармацевтическая композиция для лечения диабетической невропатии | |
Pacifici et al. | Pinazepam: a precursor of N-desmethyldiazepam | |
KR20150042232A (ko) | 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드 | |
McNamee et al. | Fenmetozole in acute alcohol intoxication in man | |
Bülow et al. | Plasma level and broncholytic effect of choline theophyllinate after a single dose of a press-coated tablet formulation | |
Tejaswi | Enhancement in Stabilityand In-Vivo Bioavailability of Rifampicin Alone and in Combination with Isoniazidusing Ascorbic Acid. | |
JPH07188002A (ja) | 鼻炎治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050209 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051125 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091201 |